Sernova Biotherapeutics Inc
SVA.TO
TSX
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -18.78% | -15.99% | -9.55% | -13.87% | 5.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -54.10% | -56.60% | -51.44% | -38.03% | -22.39% |
| Operating Income | 54.10% | 56.60% | 51.44% | 38.03% | 22.39% |
| Income Before Tax | 52.68% | 53.89% | 48.47% | 32.18% | 18.08% |
| Income Tax Expenses | 21.57% | -- | -- | -- | -- |
| Earnings from Continuing Operations | 52.66% | 53.71% | 48.35% | 32.15% | 18.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 52.66% | 53.71% | 48.35% | 32.15% | 18.07% |
| EBIT | 54.10% | 56.60% | 51.44% | 38.03% | 22.39% |
| EBITDA | 54.30% | 56.71% | 51.68% | 38.27% | 22.63% |
| EPS Basic | 56.06% | 56.83% | 50.55% | 33.60% | 18.49% |
| Normalized Basic EPS | 55.88% | 56.85% | 50.71% | 33.76% | 18.62% |
| EPS Diluted | 56.06% | 56.83% | 50.55% | 33.60% | 18.49% |
| Normalized Diluted EPS | 55.88% | 56.85% | 50.71% | 33.76% | 18.62% |
| Average Basic Shares Outstanding | 6.95% | 7.27% | 5.24% | 3.18% | 1.19% |
| Average Diluted Shares Outstanding | 6.95% | 7.27% | 5.24% | 3.18% | 1.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |